The Future of Immunotherapy-Based Combination Therapy in Metastatic Renal Cell Carcinoma

In the past two decades, there has been a significant improvement in the understanding of the molecular pathogenesis of Renal Cell Carcinoma (RCC). These insights in the biological pathways have resulted in the development of multiple agents targeting vascular endothelial growth factor (VEGF), as we...

Descripción completa

Detalles Bibliográficos
Autores principales: Garje, Rohan, An, Josiah, Greco, Austin, Vaddepally, Raju Kumar, Zakharia, Yousef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017064/
https://www.ncbi.nlm.nih.gov/pubmed/31936065
http://dx.doi.org/10.3390/cancers12010143

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017064/
https://www.ncbi.nlm.nih.gov/pubmed/31936065
http://dx.doi.org/10.3390/cancers12010143

Ejemplares similares